Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ALK rearrangements and resistance mutations in non-small cell lung cancer: molecular mechanisms and therapeutic implications.

Cancer chemotherapy and pharmacology - 29 Jun 2026

Bharath Palani, Iyer Sailakshmi, Velu Ankitha Vadi, Kumar D Thirumal

Abstract excerpt

Anaplastic lymphoma kinase (ALK) gene rearrangements represent one of the well-characterized oncogenic drivers in non-small cell lung cancer (NSCLC), with the EML4-ALK fusion being the most common and clinically significant rearrangement. ALK inhibitors, including crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib has significantly improved clinical outcomes in ALK-rearranged NSCLC patients. However,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Drug Resistance, Neoplasm

Share to Gene Rearrangement

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 42371103
DOI: 10.1007/s00280-026-04910-z

Genes

ALK
EML4

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ALK rearrangements and resistance mutations in non-small cell lung cancer: molecular mechanisms and therapeutic implications.PMID 42371103Read ↗

Clinical consequences of resistance to ALK inhibitors in non-small cell lung cancer.Semantic proximity Read ↗

Updated Evidence on the Mechanisms of Resistance to ALK Inhibitors and Strategies to Overcome Such Resistance: Clinical and Preclinical DataSemantic proximity Read ↗

Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies.Semantic proximity Read ↗

Crizotinib‐Resistant Mutants of EML4‐ALK Identified Through an Accelerated Mutagenesis ScreenSemantic proximity Read ↗

Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.Semantic proximity Read ↗

An interaction map of small-molecule kinase inhibitors with anaplastic lymphoma kinase (ALK) mutants in ALK-positive non-small cell lung cancer.Semantic proximity Read ↗

Anaplastic lymphoma kinase rearrangements in non-small-cell lung cancer: novel applications in diagnostics and treatment.Semantic proximity Read ↗

Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer.Semantic proximity Read ↗

ALK alterations and inhibition in lung cancer.Semantic proximity Read ↗

Brigatinib for the treatment of ALK-positive advanced non-small cell lung cancer patients.Semantic proximity Read ↗

EML4-ALK: Update on ALK InhibitorsSemantic proximity Read ↗

Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.